Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3255-3265

  Li, Hongwei ^b   Qi, Yanfei ^a   Li, Chengyao ^b   Braseth, Leah N ^a   Gao, Yongxin ^a   Shabashvili, Arseniy E ^a   Katovich, Michael J ^a   Sumners, Colin ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CASPASE 3; CASPASE 8; CASPASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANGIOTENSIN II; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GREEN FLUORESCENT PROTEINS; HUMANS; IN SITU NICK-END LABELING; MALE; MICROSCOPY, FLUORESCENCE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73149106602     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0237     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94.
3. Dijkman GA, Van Moorselaar RJ, Van Ginckel R, et al. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. J Urol 1994;151:217-22.
4. Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther 2007;15:1042-52.
5. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001;12:883-92.
6. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000;6:1632-38.
7. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
8. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239-49.
9. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14:227-41.
10. Shirakawa T, Terao S, Hinata N, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007;18:1225-32.
11. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293-99.
12. Uemura H, Ishiguro H, Kubota Y. Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 2006;6:835-44.
13. Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008;15:19-26.
14. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Novel molecular targeting therapeutics for prostate cancer. Nippon Rinsho 2005;63:339-44.
15. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995;92:10663-67.
16. Timmermans PB, Smith RD. The diversified pharmacology of angiotensin II-receptor blockade. Blood Press Suppl 1996;2:53-61.
17. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-57.
18. Wolf G, Harendza S, Schroeder R, et al. Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20. Lab Invest 2002;82:1305-17.
19. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996;122:59-67.
20. Dinh DT, Frauman AG, Somers GR, et al. Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 2002;196:213-19.
21. Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007;67:41-9.
22. Lawnicka H, Potocka AM, Juzala A, Fournie-Zaluski MC, Pawlikowski M. Angiotensin II and its fragments (angiotensins III and IV) decrease the growth of DU-145 prostate cancer in vitro. Med Sci Monit 2004;10: BR410-13.
23. Uemura H, Hasumi H, Ishiguro H, et al. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006;66:822-30.
24. Chow L, Rezmann L, Imamura K, et al. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate 2008;68:651-60.
25. Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2003;284:F955-65.
26. Cui TX, Nakagami H, Nahmias C, et al. Angiotensin II subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12W cells. Mol Endocrinol 2002;16:2113-23.
27. Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002;283:F173-80.
28. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997;272:19022-26.
29. Miura S, Karnik SS. Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 2000;19:4026-35.
30. Miura S, Karnik SS, Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem 2005;280:18237-44.
31. Shenoy UV, Richards EM, Huang XC, Sumners C. Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain. Endocrinology 1999;140:500-09.
32. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996;93:156-60.
33. Li HW, Gao YX, Raizada MK, Sumners C. Intronic enhancement of angiotensin II type 2 receptor transgene expression in vitro and in vivo. Biochem Biophys Res Commun 2005;336:29-35.
34. Li HW, Gao YX, Matsuura T, Martynyuk A, Raizada MK, Sumners C. Adenoviral-mediated neuron specific transduction of angiotensin II type 2 receptors. Regul Pept 2005;126:213-22.
35. Marcus JS, Karackattu SL, Fleegal MA, Sumners C. Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-κB. Glia 2003;41:152-60.
36. Sidorkiewicz M, Rebas E, Szymajda M, Lawnicka H, Pawlikowski M, Lachowicz A. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor. Med Sci Monit 2009;15:BR106-110.
37. Li H, Gao Y, Grobe JL, et al. Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. Am J Physiol Heart Circ Physiol 2007;292:H727-35.
38. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-08.
39. Revankar CM,Vines CM,Cimino DF, Prossnitz ER. Arrestins block G protein-coupled receptor-mediated apoptosis. J Biol Chem 2004;279:24578-84.
40. Lu Y. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Adv Drug Deliv Rev 2009;61:572-88.
41. Gotoh A, Ko SC, Shirakawa T, et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998;160:220-9.
42. Jarrard DF, Kinoshita H, Shi Y, et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 1998;58:5310-4.
43. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-34.
44. Zerbini LF, Wang Y, Correa RG, Cho JY, Libermann TA. Blockage of NF-κB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 2005;4:1247-53.